Developer of gene therapies intended to fight cancer. CarryGenes targets the use of a human synthetic chromosome technology (hSynC) for immunotherapy of cancer through effective engineering of anti-tumoral T-cells as well as broader applications beyond oncology, thereby providing medical organizations benefits in areas of high medical needs.
Cellestia is a privately-owned clinical-stage biopharma company led by an experienced team of scientists, drug developers and business professionals. The patented drug, CB-103 along with its companion diagnostic, is a small molecule with an innovative mode of action targeting NOTCH-driven cancers, and providing hope for patients with no other treatment options.
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Elicera develops four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell therapies, in addition to a platform technology called iTANK for further immune enhancement of treatment.
GPX Medical is developing neonatal intensive care product NEOLA®, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a technology that measures lung volume changes and oxygen gas concentration. NEOLA® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants.
Lumito specializes in imaging technology based on UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito’s IPR covers high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers. The technology has several possible application areas of which Lumito has initially decided to focus on digital pathology.
NanoEcho develops a unique technology to improve the diagnosis of primarily rectal cancer. The image technology is based on a combination of nano particles and magneticmotive ultrasound. The images will make it possible to identify lymph nodes affected by cancer already before surgery as well as determining a more precise location of the cancer tissue.
NeoDynamics is dedicated to diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institute in Sweden. The system is designed to provide accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
Prolight Diagnostics develops Point Of Care Testing (POCT) systems based on patented technology. POC-tests are performed outside the traditional hospital laboratories, with small mobile instruments which facilitates testing close to the patient and with quick results. Prolight has during the last decade worked on the development within “micro Elisa” for Point of Care testing.
Reccan Diagnostics develops a biotechnology platform for in vitro diagnostics, providing earlier and more specific diagnosis as well as improved prognostic stratification of solid cancers. The technology combines unique biomarkers in blood and cancer tissue. Focus is on pancreatic cancer, the third leading cause of cancer-related death, where early detection substantially improves the prognosis.
SpectraCure focuses on cancer treatments with medical systems based on laser light sources, connected to the tumour by way of optical fibers, in combination with a photoreactive drug. The method called Interstitial Photodynamic Therapy or PDT is suitable for internal solid tumours, such as prostate and pancreatic tumours, but also for example for cancers of the head and neck.
Cooling can increase survival chances after critical illnesses by reducing the risk of brain damage caused by oxygen deprivation. TEQCool offers a unique brain and body cooling system. The QuickCool® TTM System apply the cooling via the nasal cavity and is an easy-to-use, portable, and optimized for cooling of cardiac arrest patients at 36°C.